229 related articles for article (PubMed ID: 32174756)
1. Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
Elkrief A; Alcindor T
Curr Oncol; 2020 Feb; 27(Suppl 1):34-40. PubMed ID: 32174756
[TBL] [Abstract][Full Text] [Related]
2. Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.
Ray A; Huh WW
Curr Oncol Rep; 2012 Aug; 14(4):311-9. PubMed ID: 22535507
[TBL] [Abstract][Full Text] [Related]
3. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Reed D; Altiok S
Cancer Control; 2011 Jul; 18(3):188-95. PubMed ID: 21666581
[TBL] [Abstract][Full Text] [Related]
4. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy in pediatric-type soft-tissue sarcoma.
Ingley KM; Cohen-Gogo S; Gupta AA
Curr Oncol; 2020 Feb; 27(Suppl 1):6-16. PubMed ID: 32174753
[TBL] [Abstract][Full Text] [Related]
6. Update on systemic therapy for advanced soft-tissue sarcoma.
Smrke A; Wang Y; Simmons C
Curr Oncol; 2020 Feb; 27(Suppl 1):25-33. PubMed ID: 32174755
[TBL] [Abstract][Full Text] [Related]
7. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Gan M; Zhang C; Qiu L; Wang Y; Bao H; Yu R; Liu R; Wu X; Shao Y; Hou P; Fei Z
Cancer Med; 2022 Nov; 11(21):4070-4078. PubMed ID: 35586877
[TBL] [Abstract][Full Text] [Related]
9. Novel treatment strategies for soft tissue sarcoma.
Kasper B; Gil T; D'Hondt V; Gebhart M; Awada A
Crit Rev Oncol Hematol; 2007 Apr; 62(1):9-15. PubMed ID: 17141519
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH; Litière S; Sleijfer S; Benson C; Italiano A; Kasper B; Messiou C; Gelderblom H; Wardelmann E; Le Cesne A; Blay JY; Marreaud S; Hindi N; Desar IME; Gronchi A; van der Graaf WTA
Int J Cancer; 2018 Jun; 142(12):2610-2620. PubMed ID: 29383713
[TBL] [Abstract][Full Text] [Related]
12. Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.
Skafida E; Kokkali S; Nikolaou M; Digklia A
Expert Rev Anticancer Ther; 2017 Jun; 17(6):537-543. PubMed ID: 28425820
[TBL] [Abstract][Full Text] [Related]
13. (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair.
Saponara M; Stacchiotti S; Casali PG; Gronchi A
Eur J Cancer; 2017 Jan; 70():1-11. PubMed ID: 27866094
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?
Meissner M; Napolitano A; Thway K; Huang P; Jones RL
Expert Opin Pharmacother; 2023; 24(12):1395-1401. PubMed ID: 37326105
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
16. New emerging drugs in soft tissue sarcoma.
Milano A; Apice G; Ferrari E; Fazioli F; de Rosa V; de Luna AS; Iaffaioli RV; Caponigro F
Crit Rev Oncol Hematol; 2006 Jul; 59(1):74-84. PubMed ID: 16533604
[TBL] [Abstract][Full Text] [Related]
17. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
Harwood JL; Alexander JH; Mayerson JL; Scharschmidt TJ
Orthop Clin North Am; 2015 Oct; 46(4):587-608. PubMed ID: 26410647
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
19. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma.
Todd R; Lunec J
Expert Rev Anticancer Ther; 2008 Jun; 8(6):939-48. PubMed ID: 18533803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]